Skip to main content

Gilead Sciences ratios

  • GILD · Nasdaq
  • Biotechnology
  • S&P 500
$168.08+0.08%Close 13 Nov 2026 · Market value $210.1B

In fiscal 2025 (the year to 31 Dec 2025), Gilead Sciences had an operating margin of 34.0%, a return on equity of 40.5%, a return on invested capital of 20.4%.

From Gilead Sciences's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025.

Annual

Gilead Sciences ratios, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Gross margin81.8%78.9%77.2%76.5%74.7%74.5%74.5%84.8%87.7%86.0%83.3%78.1%79.2%81.5%75.8%79.3%76.0%78.3%78.8%
Operating margin51.2%50.2%50.3%49.8%45.2%41.3%40.4%61.3%68.0%58.0%54.1%37.1%19.1%16.5%36.3%26.9%28.0%5.8%34.0%
Net margin37.5%37.1%37.6%36.5%33.4%26.7%27.5%48.6%55.5%44.4%17.7%24.7%24.0%0.5%22.8%16.8%20.9%1.7%28.9%
Free cash flow margin37.6%38.0%40.6%34.9%41.8%28.8%26.0%49.3%62.8%53.6%43.3%33.8%37.1%30.5%39.6%30.6%27.4%35.8%32.1%
Return on equity42.2%49.3%49.5%47.4%44.5%32.3%29.7%90.3%107%72.2%23.5%26.1%24.5%0.6%31.7%21.7%25.7%2.3%40.5%
Return on assets—28.5%31.8%27.5%20.0%14.8%15.0%43.3%43.0%25.6%17.5%8.6%5.4%4.9%10.9%8.8%9.9%1.9%14.8%
Return on capital employed—46.9%52.1%46.7%31.7%25.2%27.3%67.7%62.8%39.4%26.5%14.7%8.2%7.5%17.5%13.5%14.8%3.4%21.3%
Return on invested capital—49.7%51.5%41.6%45.4%26.7%18.9%65.8%77.2%42.1%28.4%16.0%10.5%7.2%13.5%10.9%12.6%2.6%20.4%
Current ratio—3.502.572.325.531.451.093.072.502.122.743.383.101.401.271.291.431.601.55
Debt to equity—0.260.180.701.130.880.580.801.191.391.641.281.121.761.301.221.121.411.13
Net debt / EBITDA—−0.25−0.140.50−0.581.530.970.140.320.770.52−0.290.174.451.742.061.793.911.40
Interest coverage34.2641.0550.6636.3618.4511.1114.7437.0532.2618.2912.637.614.314.149.917.848.061.709.79
Cash conversion100%103%108%95.5%125%108%94.8%101%113%121%244%137%154%6112%174%182%131%2147%111%
Dividend payout——————0.0%0.0%10.3%18.2%59.0%54.5%59.8%2804%57.9%80.8%67.2%816%47.0%
SBC / Revenue4.4%2.9%2.6%2.5%2.3%2.2%2.2%1.4%1.2%1.3%2.4%3.8%2.8%2.6%2.3%2.3%2.8%2.9%3.0%

Quarterly

Gilead Sciences ratios, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Gross margin70.6%76.8%77.8%79.1%79.1%76.9%78.8%79.8%79.5%79.2%79.8%81.1%
Operating margin22.7%−64.6%38.0%11.8%32.4%33.6%34.9%42.8%25.0%37.2%−133%41.7%
Net margin20.1%−62.4%23.2%16.6%23.6%19.7%27.7%39.3%27.5%29.0%−135%29.3%
Free cash flow margin27.5%31.6%17.2%55.2%37.4%24.8%10.2%51.0%39.4%34.9%44.0%57.8%
Return on equity6.3%−23.8%8.8%6.8%9.2%6.9%10.0%14.2%9.6%8.6%−88.7%18.6%
Return on assets2.2%−6.1%3.9%1.3%3.4%3.2%3.6%4.8%2.7%3.6%−16.6%5.3%
Return on capital employed3.2%−10.0%6.2%2.1%5.2%5.1%5.6%7.2%4.2%5.5%−27.1%8.8%
Return on invested capital2.9%−7.4%4.8%1.7%4.8%4.2%4.6%6.4%3.6%5.0%−21.7%7.4%
Current ratio1.431.081.141.261.601.371.321.451.551.971.271.38
Debt to equity1.121.441.281.261.411.301.271.161.130.942.222.01
Net debt / EBITDA8.00—6.1611.545.515.806.234.386.704.44—4.71
Interest coverage6.40−17.0211.163.739.858.609.7413.007.7810.78−42.0812.87
Cash conversion137%−50.7%74.0%333%159%126%36.7%130%143%120%−32.7%198%
Dividend payout66.0%—60.2%78.5%54.6%76.8%50.7%32.9%45.5%51.5%—42.8%
SBC / Revenue2.8%2.8%3.0%2.9%2.9%3.1%3.2%3.0%2.9%3.1%3.0%2.8%

The main figures as JSON and plain text. See data and methodology.

GILD in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.